Skip to main content
YD Bio Ltd logo

YD Bio Ltd — Investor Relations & Filings

Ticker · YDES ISIN · KYG983011076 US Professional, scientific and technical activities
Open in API
Filings indexed 55 across all filing types
Latest filing 2026-03-26 Director's Dealing
Country US United States of America
Listing US YDES

About YD Bio Ltd

http://ir.ydesgroup.com/

YD Bio Ltd. is a biotechnology company that develops solutions for early cancer detection and regenerative medicine. The company's primary focus is on creating non-invasive, blood-based diagnostic tests for various cancers, including pancreatic and colorectal, through its OkaiDx™ testing portfolio. In parallel, YD Bio is advancing next-generation cell therapies, utilizing stem cell and exosome-based technologies. These therapeutic initiatives target applications in areas such as ophthalmology, with programs like its LSC Exosome Therapeutics. The company aims to improve patient lives by making its diagnostic and therapeutic innovations accessible.

Recent filings

Filing Released Lang Actions
3 - YD Bio Ltd (0002011674) (Issuer)
Director's Dealing
2026-03-26 English
3 - YD Bio Ltd (0002011674) (Issuer)
Director's Dealing
2026-03-18 English
SCHEDULE 13G/A Filing
Major Shareholding Notification
2026-02-17 English
424B3 Filing
M&A Activity Classification · 95% confidence The document is a Form 6-K filed by YD Bio Limited, which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. It includes a detailed announcement of entering into a binding Letter of Intent (LOI) to acquire Safe Save Medical Cell Sciences & Technology Co., Ltd. The document discusses the terms of the LOI, the expected transaction structure, consideration, and conditions precedent. It also includes a press release as an exhibit that elaborates on the strategic rationale and details of the acquisition. The content is focused on merger and acquisition activity, specifically an acquisition LOI, and does not contain full financial statements or quarterly/annual report data. Therefore, the document fits best into the M&A Activity category (Code: TAR).
2026-02-05 English
6-K Filing
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by a foreign private issuer, YD Bio Limited, reporting the entry into a Letter of Intent to acquire another company. It includes details about the transaction terms, conditions, and expected timeline. The document also includes a press release as an exhibit. Form 6-K filings are periodic reports submitted by foreign private issuers to disclose material information that is not required to be reported on Form 20-F or 40-F. This filing is an announcement of a corporate transaction and does not contain comprehensive financial statements or detailed financial analysis. It is not an annual or interim report, audit report, earnings release, or any other detailed financial report. It is also not a proxy, voting result, or governance document. The content fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements and disclosures that do not fit other specific categories.
2026-01-30 English
REPORT OF FOREIGN PRIVATE ISSUER
Board/Management Information Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign private issuer filed with the SEC. It contains announcements about appointments to the Board of Directors and committee memberships, as well as a notification about compliance with Nasdaq listing rules. There are no financial statements or detailed financial data present. The document is relatively short (2681 characters) and serves as a regulatory announcement of management changes and compliance status. Therefore, it fits best under Board/Management Information (MANG).
2026-01-21 English

Browse filings by year

3 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.